EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Predictors of Long-Term Survival in Patients with Idiopathic Pulmonary Fibrosis: Data from the IPF-PRO Registry

Hyun J Kim iD, Jeremy M Weber, Megan L Neely iD, Amy Hajari Case, Aiham H Jbeli, Peide Li, Amy L Olson iD, Laurie D Snyder iD, IPF-PRO Registry investigators

Lung · 2025-12 · 203 (1)

DOI: 10.1007/s00408-025-00797-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Lung, online erschienen am 09.03.2025. Verfasst von Hyun J Kim und 8 weiteren Autor:innen. Beteiligte Einrichtung: University of Minnesota, 420 Delaware St. SE, Minneapolis, MN, 55455, USA. kimxx015@umn.edu. Hauptthemen laut MEDLINE: Idiopathic Pulmonary Fibrosis. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The IPF-PRO/ILD-PRO Registry is supported by Boehringer Ingelheim Pharmaceuticals, Inc and run in collaboration with the Duke Clinical Research Institute and e….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: We used data from the IPF-PRO Registry of patients with idiopathic pulmonary fibrosis (IPF) to identify characteristics that predicted survival for a further > 5 years. METHODS: Participants had IPF that was diagnosed or confirmed at the enrolling center in the previous 6 months. Patients were followed prospectively. A Classification And Regression Tree (CART) was used to identify predictors of survival > 5 versus ≤ 5 years following enrollment. The following variables, assessed at enrollment, were considered: age; body mass index (BMI); former smoker; current smoker; time from first imaging evidence, symptoms, or diagnosis of IPF to enrollment; forced vital capacity (FVC) % predicted; diffusing capacity of the lungs for carbon monoxide (DLco) % predicted; antifibrotic drug use; supplemental oxygen use; history of cardiac disease; pulmonary hypertension; COPD/emphysema; and rural location. RESULTS: The analysis cohort comprised 819 patients, of whom 278 (33.9%) survived > 5 years. DLco % predicted, supplemental oxygen use and FVC % predicted were the most important variables for predicting survival > 5 versus ≤ 5 years after enrollment. The importance of these variables (scaled such that the most important had an importance of 100%) was 100%, 78.2% and 74.2%, respectively. The optimism-corrected area under the curve (AUC) of the CART was 0.72, with an accuracy of 0.72. CONCLUSION: Among patients enrolled in the IPF-PRO Registry, a decision tree that included DLco % predicted, oxygen use and FVC % predicted facilitated the prediction of survival > 5 years. Understanding predictors of longer-term survival may facilitate conversations with patients about their prognosis and treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Idiopathic Pulmonary FibrosisHumansRegistriesMaleFemaleAgedMiddle AgedVital CapacityPulmonary Diffusing CapacityTime FactorsPrognosisProspective StudiesOxygen Inhalation TherapyAntifibrotic AgentsSmokingRisk FactorsBody Mass IndexAge Factors

Stichwörter der Autor:innen

Interstitial lung diseasesMortalityObservational studyPrognosis

Substanzen

Antifibrotic Agents

Autor:innen und Institutionen

  • University of Minnesota, 420 Delaware St. SE, Minneapolis, MN, 55455, USA. kimxx015@umn.edu.
  • Duke Clinical Research Institute, Durham, NC, USA.
  • Duke University Medical Center, Durham, NC, USA.
  • Piedmont Healthcare, Atlanta, GA, USA.
  • University of Minnesota, 420 Delaware St. SE, Minneapolis, MN, 55455, USA.
  • Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA.

ORCID-Profile: Hyun J Kim, Megan L Neely, Amy L Olson, Laurie D Snyder

Förderung

  • The IPF-PRO/ILD-PRO Registry is supported by Boehringer Ingelheim Pharmaceuticals, Inc and run in collaboration with the Duke Clinical Research Institute and e…

Zitieren

APA

Kim, H. J., Weber, J. M., Neely, M. L., Case, A. H., Jbeli, A. H., Li, P., Olson, A. L., Snyder, L. D., & IPF-PRO Registry investigators (2025). Predictors of Long-Term Survival in Patients with Idiopathic Pulmonary Fibrosis: Data from the IPF-PRO Registry. Lung, 203(1). https://doi.org/10.1007/s00408-025-00797-4

Vancouver

Kim HJ, Weber JM, Neely ML, Case AH, Jbeli AH, Li P, et al. Predictors of Long-Term Survival in Patients with Idiopathic Pulmonary Fibrosis: Data from the IPF-PRO Registry. Lung. 2025;203(1). doi:10.1007/s00408-025-00797-4

BibTeX
@article{Kim2025,
  author = {Kim, Hyun J and Weber, Jeremy M and Neely, Megan L and Case, Amy Hajari and Jbeli, Aiham H and Li, Peide and Olson, Amy L and Snyder, Laurie D and IPF-PRO Registry investigators, IPF-PRO Registry investigators},
  title = {Predictors of Long-Term Survival in Patients with Idiopathic Pulmonary Fibrosis: Data from the IPF-PRO Registry},
  journal = {Lung},
  year = {2025},
  volume = {203},
  number = {1},
  doi = {10.1007/s00408-025-00797-4}
}
Kostenlos starten →